Logo

AVD

American Vanguard Corporation

AVD

American Vanguard Corporation • NYSE
$4.66 ▲ 4.02% (+0.18)
Market Cap $132.65 M
52w High $6.33
52w Low $3.28
Dividend Yield 0.12%
P/E -1.17
Volume 77.11K
Outstanding Shares 28.47M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $119.313M ▼ $40.719M ▲ $-12.358M ▼ -10.358% ▼ $-0.43 ▼ $-3.037M ▼
Q2-2025 $129.313M ▲ $36.181M ▲ $-849K ▲ -0.657% ▲ $-0.03 ▲ $8.734M ▲
Q1-2025 $115.8M ▼ $34.501M ▼ $-8.462M ▲ -7.307% ▲ $-0.3 ▲ $200K ▲
Q4-2024 $165.647M ▲ $92.869M ▲ $-90.429M ▼ -54.591% ▼ $-3.21 ▼ $-11.339M ▲
Q3-2024 $118.307M $45.681M $-25.742M -21.759% $-0.91 $-22.651M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $16.795M ▲ $655.013M ▲ $434.025M ▲ $220.988M ▼
Q2-2025 $14.482M ▲ $651.978M ▲ $421.156M ▲ $230.822M ▲
Q1-2025 $11.805M ▼ $631.588M ▼ $404.234M ▲ $227.354M ▼
Q4-2024 $12.514M ▲ $636.721M ▼ $403.611M ▼ $233.11M ▼
Q3-2024 $11.88M $759.458M $431.55M $327.908M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-12.358M ▼ $12.692M ▲ $-985K ▼ $-9.417M ▼ $2.313M ▼ $11.266M ▲
Q2-2025 $-849K ▲ $-19.26M ▲ $-611K ▼ $21.678M ▲ $2.677M ▲ $-19.849M ▲
Q1-2025 $-8.462M ▲ $-20.576M ▼ $-446K ▼ $19.801M ▲ $-709K ▼ $-21.034M ▼
Q4-2024 $-90.429M ▼ $33.772M ▲ $-242K ▼ $-32.284M ▲ $634K ▲ $32.531M ▲
Q3-2024 $-25.742M $27.879M $17K $-34.737M $-6.069M $26.717M

Revenue by Products

Product Q3-2019Q4-2019Q1-2023Q4-2023
U S Crop
U S Crop
 $0 ▲$0 ▲$60.00M ▲$210.00M ▲
U S Non Crop
U S Non Crop
 $0 ▲$0 ▲$10.00M ▲$60.00M ▲
Amount Of Herbicides Sold
Amount Of Herbicides Sold
 $50.00M ▲$70.00M ▲$0 ▼$0 ▲
Amount Of Insecticides Sold
Amount Of Insecticides Sold
 $40.00M ▲$40.00M ▲$0 ▼$0 ▲
Crop
Crop
 $0 ▲$110.00M ▲$0 ▼$0 ▲
Non Crop Including Distribution Of Third Party Products
Non Crop Including Distribution Of Third Party Products
 $20.00M ▲$0 ▼$0 ▲$0 ▲
Other Including Plant Growth Regulators And Distribution
Other Including Plant Growth Regulators And Distribution
 $20.00M ▲$0 ▼$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Sales have grown over the longer term but appear to have peaked recently and then slipped, suggesting a tougher demand or pricing environment. Profitability has weakened: margins have narrowed, operating profit has swung from modestly positive to clearly negative, and the company moved from small profits to a notable loss in the most recent year. This points to cost pressures, possible inventory or write-down issues, and a business that is currently not covering its operating costs with revenue.

Balance Sheet

Balance Sheet The company still has a sizable asset base, but its financial cushion has shrunk. Shareholders’ equity has stepped down, reflecting recent losses. Debt has climbed compared with a few years ago, though from a relatively low starting point, which means leverage is higher but not extreme. Cash on hand is quite thin, so the balance sheet has less room for error than before and depends heavily on future cash generation and credit access.

Cash Flow

Cash Flow Cash generation has become a concern. The business used to produce steady, positive cash flow from operations and solid free cash flow; over the last two years this has faded to weak or negative levels. Capital spending has remained fairly modest and stable, so the problem is more about cash coming in from the core business than about heavy investment. This pattern suggests working capital strain and lower profitability are weighing on actual cash in the door.

Competitive Edge

Competitive Edge American Vanguard occupies a specialized position in agricultural inputs, focusing on niche crops, turf and ornamentals, and public health rather than the most hotly contested row-crop markets. Its mix of acquired, proven chemistries and newer, sustainability-focused products gives it breadth and resilience. Ownership of manufacturing sites and a broad distribution network add reliability and some cost control. However, the company operates in a cyclical, weather- and commodity-driven industry and still competes against much larger global players, so its niche and technology advantages must continually offset that scale gap.

Innovation and R&D

Innovation and R&D Innovation is a clear bright spot. The GreenSolutions line of biologicals and specialty nutrition products positions the company well for the long-term shift toward sustainable and organic-friendly farming. The SIMPAS and Ultimus precision application technologies are differentiated, tying product sales to a data-rich, hardware-and-software platform that can deepen customer relationships. A steady flow of product acquisitions, partnerships in biologicals, and ongoing development of new formulations and combinations all point to a company investing meaningfully in future growth, even as current financial results are under pressure.

Summary

American Vanguard combines an attractive strategic story with currently weak financial results. On one hand, it has carved out defensible niches, built a differentiated portfolio in sustainable inputs and precision application, and assembled a meaningful innovation pipeline. On the other hand, recent performance shows slipping sales, eroded margins, operating losses, and softer cash flow, which have reduced its financial buffer and increased reliance on debt and future recovery. The key questions going forward are whether its biologicals and precision technologies can scale fast enough, and whether management can restore profitability and cash generation, to bring the financials back in line with the company’s strategic promise.

NEWS

November 10, 2025 · 8:00 AM UTC

American Vanguard Reports Third Quarter 2025 Results

Read more